CLDN6 and neoplasm: CLDN6 caused an increase in mitochondrial membrane density and lipid droplet, and a decrease in mitochondrial cristae, which were aggravated after treatment with sorafenib as observed by TEM in xenograft tumor tissue (Fig. 6C).